Association of plant-based diet index with quality of life in patients with prostate cancer.

Authors

null

Stacy Loeb

New York University and Manhattan Veterans Affairs, New York, NY

Stacy Loeb , Qi Hua , Scott Bauer , Stacey A. Kenfield , Alicia K. Morgans , Lorelei A Mucci

Organizations

New York University and Manhattan Veterans Affairs, New York, NY, Harvard School of Public Health, Boston, MA, University of California San Francisco, San Francisco, CA, Departments of Urology and Epidemiology & Biostatistics, University of San Francisco California, San Francisco, CA, Dana-Farber Cancer Institute, Boston, MA, Harvard School of Public Health & Nutrition, Boston, MA

Research Funding

Other Government Agency
New York State Department of Health, NYU Perlmutter Cancer Center

Background: Plant-based diets have many health benefits including a lower risk of fatal prostate cancer. Less is known about the relationship between diet and functional outcomes among prostate cancer survivors. We hypothesized that greater consumption of plant-based food after prostate cancer diagnosis is associated with improved quality of life (QOL). Methods: This prospective cohort study included 3,505 participants in the Health Professionals Follow-up Study with non-metastatic prostate cancer (1986-2016). Overall and healthful Plant-based Diet Indices were calculated from food frequency questionnaires with cumulative updating. QOL scores were calculated using the Expanded Prostate Cancer Index Composite. Generalized estimating equations were used to examine associations between Plant-based Diet Indices and 5 QOL domains, adjusted for clinical and demographic factors. Results: Higher Plant-Based Diet Index was associated with improved scores for sexual function, urinary irritation/obstruction, and urinary incontinence among men with prostate cancer. Consuming more healthful plant-based foods was also associated with better scores for bowel function and hormonal/vitality in the age-adjusted models. Results were similar in sensitivity analyses excluding patients with pre-existing erectile dysfunction or lower urinary tract symptoms, and adjusting for use of sexual or urinary medications. A limitation is that no participants followed a strict vegan diet. Conclusions: This prospective study suggests that greater consumption of healthful plant-based foods is associated with modest improvements in QOL domains among patients with prostate cancer.

Generalized estimating equation models for 5 quality of life domains, including mean differences between dietary index highest (Q5) and lowest quintile (Q1), and p-trend across quintiles.

Plant Diet Index
Diff Q5-Q1 (95% CI), p-trend
Healthful Plant-Diet Index
Diff Q5-Q1 (95% CI), p-trend
Sexual
Model 1
Model 2

-0.76 (-1.08, -0.44), p<0.0001
-0.36 (-0.73-0.00), p=0.02

-0.78(-1.09,-0.46), p<0.0001
-0.60(-0.94,-0.26), p<0.0001
Urinary Irritation/Obstruction
Model 1
Model 2

-0.07 (-0.25, 0.10), p=0.17
-0.21 (-0.41, -0.01), p=0.01

-0.17 (-0.35, 0.02), p=0.07
0.01 (-0.20, 0.21), p=0.82
Urinary Incontinence
Model 1
Model 2

-0.15 (-0.40, 0.09), p=0.13
-0.26 (-0.54, 0.02), p=0.03

-0.41 (-0.66, -0.15), p<0.0001
-0.20 (-0.48, 0.07), p=0.2
Bowel
Model 1
Model 2

0.0 (-0.19, 0.20), p=0.56
-0.12 (-0.36, 0.11), p=0.54

-0.41 (-0.60, -0.22), p<0.0001
-0.20 (-0.41, 0.00), p=0.1
Hormonal/Vitality
Model 1
Model 2

-0.13 (-0.29, 0.03), p=0.08
-0.13 (-0.32, 0.06), p=0.12

-0.29 (-0.45,-0.13), p<0.0001
-0.08 (-0.25-0.10), p=0.46

Model 1 is adjusted for age and time. Model 2 is also adjusted for PSA, grade, stage, body mass index, physical activity, calories, smoking, alcohol, diabetes, heart disease, stroke and hypertension.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5037)

DOI

10.1200/JCO.2023.41.16_suppl.5037

Abstract #

5037

Poster Bd #

131

Abstract Disclosures

Similar Abstracts